Ask AI
ProCE Banner Activity

Unmasking EGPA: Expert Strategies for Delivering Guideline-Concordant Care

Clinical Thought

Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare systemic vasculitis. In this commentary, experts answer key learner questions on how to provide guideline-concordant care when confirming an EGPA diagnosis and using immunosuppressive agents like glucocorticoids and rituximab in EGPA treatment.

Released: November 05, 2025

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by an educational grant from AstraZeneca.

AstraZeneca

Disclosure

Primary Author

Praveen Akuthota, MD: consultant/advisor/speaker: Amgen, AstraZeneca, Connect Biopharma, Envada Biosciences, GlaxoSmithKline, Sanofi, Vida Ventures.

Michael E. Wechsler, MD, MMSc: consultant/advisor/speaker: Allakos, Amgen, Areteia, Arrowhead, AstraZeneca, Avalo, Belenos Bio, Celldex, Connect Biopharma, GlaxoSmithKline, Enveda, Equillium, General Medicines, Jasper, Kinaset, Kymera, Lilly, Merck, myBiometry, Pharming, Phylaxis, Pulmatrix, Rapt, Recludix Pharma, Regeneron, Roche/Genentech, Sanofi/Genzyme, Sentien, Sound Biologics, Teherex, Uniquity Bio, Verona Pharma, Zurabio; researcher: Amgen, AstraZeneca, GlaxoSmithKline, Regeneron, Sanofi/Genzyme, Upstream Bio; individual publicly traded stock/stock options: Upstream Bio.